These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37806829)

  • 41. Preoperative anemia: impact on short- and long-term outcomes following curative-intent resection of gastroenteropancreatic neuroendocrine tumors.
    Xiang JX; Nan YL; He J; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Lv Y; Zhang XF; Pawlik TM
    J Gastrointest Surg; 2024 Jun; 28(6):852-859. PubMed ID: 38538480
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors.
    Cai Y; Liu Z; Jiang L; Ma D; Zhou Z; Ju H; Zhu Y
    Front Endocrinol (Lausanne); 2022; 13():871830. PubMed ID: 35937823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
    Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
    Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database.
    Mao R; Zhao H; Li K; Luo S; Turner M; Cai JQ; Blazer D
    Ann Surg Oncol; 2019 Sep; 26(9):2722-2729. PubMed ID: 31209670
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
    Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
    Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases.
    Tierney JF; Poirier J; Chivukula S; Pappas SG; Hertl M; Schadde E; Keutgen X
    Int J Endocrinol; 2019; 2019():9871319. PubMed ID: 30992703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract.
    Gibson WE; Gonzalez RS; Cates JMM; Liu E; Shi C
    Hum Pathol; 2018 Sep; 79():109-115. PubMed ID: 29763717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors.
    Partelli S; Maurizi A; Tamburrino D; Baldoni A; Polenta V; Crippa S; Falconi M
    Eur J Endocrinol; 2014 Oct; 171(4):R153-62. PubMed ID: 24920289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center.
    Pape UF; Böhmig M; Berndt U; Tiling N; Wiedenmann B; Plöckinger U
    Ann N Y Acad Sci; 2004 Apr; 1014():222-33. PubMed ID: 15153439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
    Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: A propensity score matching study.
    Mao K; Yan Y; Zhang J; Wang J; Wang R; Ling X; Liu Y; Lau WY; Jiang S; Liu J; Xiao Z
    Cancer Med; 2018 Sep; 7(9):4475-4484. PubMed ID: 30117307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term survival in laparoscopic vs open resection for colorectal liver metastases: inverse probability of treatment weighting using propensity scores.
    Lewin JW; O'Rourke NA; Chiow AKH; Bryant R; Martin I; Nathanson LK; Cavallucci DJ
    HPB (Oxford); 2016 Feb; 18(2):183-191. PubMed ID: 26902138
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
    Grillo F; Albertelli M; Brisigotti MP; Borra T; Boschetti M; Fiocca R; Ferone D; Mastracci L
    Neuroendocrinology; 2016; 103(5):452-9. PubMed ID: 26337010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of surgery for gastric cancer with distant metastases: a retrospective study from the SEER database.
    Chen J; Kong Y; Weng S; Dong C; Zhu L; Yang Z; Zhong J; Yuan Y
    Oncotarget; 2017 Jan; 8(3):4342-4351. PubMed ID: 28008147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases.
    Siebenhüner AR; Güller U; Warschkow R
    BMC Cancer; 2020 Mar; 20(1):246. PubMed ID: 32293337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
    Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
    J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours.
    Chiramel J; Almond R; Slagter A; Khan A; Wang X; Lim KHJ; Frizziero M; Chakrabarty B; Minicozzi A; Lamarca A; Mansoor W; Hubner RA; Valle JW; McNamara MG
    World J Clin Oncol; 2020 Apr; 11(4):205-216. PubMed ID: 32355642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.
    Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
    Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
    J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.